# EDGAR Filing Document

**Accession Number:** 0001541157
**File Stem:** 0001493152-26-003763
**Filing Date:** 2026-1
**Character Count:** 2417
**Document Hash:** 767c8453588b087fb1ab24eab4cdb036
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-003763.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0001493152-26-003763

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akari Therapeutics Plc
- **CENTRAL INDEX KEY:** 0001541157
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981034922
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602
- **BUSINESS PHONE:** (929) 274-7510

**MAIL ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsus Therapeutics Plc.
- **DATE OF NAME CHANGE:** 20130621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Morria Biopharmaceuticals PLC
- **DATE OF NAME CHANGE:** 20120201

**Akari Therapeutics, Plc**

**401 East Jackson St, Suite 3300**

**Tampa, FL 33602**

January 27, 2026

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549-7553

Re: Akari Therapeutics, Plc <br> Registration Statement on Form S-1 <br> Filed January 23, 2026 (File No. 333-292930)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the "***Company***") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-292930) (the "***Registration Statement***") be accelerated so that the Company's Registration Statement will become effective at 4:15 P.M., Eastern Time, on January 29, 2026, or as soon thereafter as is practicable.

Please contact Gary Emmanuel, Esq. of Greenberg Traurig, P.A, counsel to the Company, at 212 801 9337 to provide notice of effectiveness, or if you have any questions or comments concerning this request.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **AKARI THERAPEUTICS, PLC** | **AKARI THERAPEUTICS, PLC** |
| By: | /s/ Abizer Gaslightwala |
| Name: | Abizer Gaslightwala |
| Title: | President and Chief Executive Officer |

---